Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

Overview of attention for article published in PharmacoEconomics, June 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 38,637 followers.

RT @Aiims1742: Cost effectiveness of first line treatment for metastatic #PancreaticCancer USA: https://t.co/g47pJg3bBF (Threshold of $200…

Quality of life vs Cost-effectiveness vs Evidence-based treatment. Should patients really have to choose what’s most important to them? #FightingCancer #clinicaltrials https://t.co/3u9VPBWXH1

RT @Aiims1742: Cost effectiveness of first line treatment for metastatic #PancreaticCancer USA: https://t.co/g47pJg3bBF (Threshold of $200…

RT @Aiims1742: Cost effectiveness of first line treatment for metastatic #PancreaticCancer USA: https://t.co/g47pJg3bBF (Threshold of $200…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.